A Toolkit for Healthcare Transition for Adolescents With Classical Myeloproliferative Neoplasms
Nicole Kucine1, Holger Cario2, Ghaith Abu-Zeinah1
1Weill Cornell Medicine, New York, New York, USA.
Adolescent myeloproliferative neoplasms (MPNs) require better healthcare transition strategies. Experts developed tools—physician education, readiness assessment, and practice recommendations—to improve care for young MPN patients moving to adult medicine.
Area of Science:
- Hematology
- Pediatric Oncology
- Adolescent Medicine
Background:
- Classical myeloproliferative neoplasms (MPNs) are increasingly diagnosed in adolescents.
- Existing healthcare transition protocols are insufficient for young MPN patients.
- A structured approach is needed for transitioning MPN care from pediatric to adult settings.
Purpose of the Study:
- To develop tools for facilitating high-quality healthcare transition for adolescent MPN patients.
- To address the lack of specific guidance for MPN patient transitions.
- To improve continuity of care for young adults with MPNs.
Main Methods:
- Convened an international expert panel in pediatric and adult MPN care.
- Developed three distinct tools: a physician education module, a transition readiness assessment, and a consensus-based practice recommendations statement.
- Focused on creating resources for a seamless transition process.
Main Results:
- Successfully developed a physician education tool to enhance provider knowledge.
- Created a transition readiness assessment tool for evaluating patient preparedness.
- Established a consensus statement outlining practice recommendations for MPN healthcare transitions.
Conclusions:
- The developed tools aim to significantly improve the healthcare transition experience for adolescents with MPNs.
- These resources provide a framework for managing the complexities of transitioning young patients to adult care.
- Further evaluation of the readiness assessment tool with adolescent patients is planned.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Preclinical Development: Overview
